41337-78-4

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 6-ethylpicolinate serves as a crucial building block in the synthesis of various pharmaceuticals. Its unique structure allows it to be a versatile component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, Ethyl 6-ethylpicolinate is utilized as an intermediate in the production of pesticides and other agrochemicals. Its role in this industry is vital for the synthesis of compounds that help protect crops and enhance agricultural productivity.
Used in Fragrance and Flavor Industry:
Ethyl 6-ethylpicolinate also finds applications in the fragrance and flavor industry due to its slightly fruity odor. It can be used to create or modify scents and tastes in various consumer products, adding value to the final product's sensory experience.
Used in Organic Synthesis:
As a building block in organic synthesis, Ethyl 6-ethylpicolinate is instrumental in the production of a wide range of fine chemicals. Its versatility in chemical reactions makes it a valuable component in the synthesis of specialty chemicals for various industries.

Upstream product

• 134370-37-9 Ethyl 5-(2-Oxobutyl)-2-isoxazoline-3-carboxylate 
• 688-99-3 5-hexen-3-ol 
• 202817-14-9 ethyl 5-(2-hydroxybutyl)-2-isoxazoline-3-carboxylate 
• 1383474-28-9 ethyl 6-vinylpicolinate 
• 1629-58-9 4-penten-3-one 
• 28051-72-1 Ethyl-vinyl-keton-oxim 
• 140-88-5 ethyl acrylate 
• 21190-89-6 6-chloropyridine-2-carboxylic acid ethyl ester 

Downstream Products

• 162739-97-1 N-methyl-N-<(6-ethyl-2-pyridinyl)methyl>amine 
• 153646-82-3 6-ethyl-2-pyridinecarboxaldehyde 
• 163658-33-1 6-ethyl-2-(hydroxymethyl)pyridine 

Relevant academic research and scientific papers

BENZOTRIAZOLE-DERIVED AND UNSATURATED AMIDE COMPOUND USED AS TGF- R1 INHIBITOR

A benzotriazole-derived α and β-unsaturated amide compound used as TGF-βR1 inhibitor or a pharmaceutically acceptable salt thereof, the structure of the compound being as shown in formula (I).

Rh(III)-catalyzed regioselective synthesis of pyridines from alkenes and α,β-unsaturated oxime esters

α,β-Unsaturated O-pivaloyl oximes are coupled to alkenes by Rh(III) catalysis to afford substituted pyridines. The reaction with activated alkenes is exceptionally regioselective and high-yielding. Mechanistic studies suggest that heterocycle formation proceeds via reversible C-H activation, alkene insertion, and a C-N bond formation/N-O bond cleavage process.

SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption. Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 μM) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

RETROVIRAL PROTEASE INHIBITING COMPOUNDS

A retroviral protease inhibiting compound of the formula: STR1 is disclosed wherein R 1, R 2, R 5, R 6, Y m and Y' n are herein defined.